Drug Interactions between dabrafenib and fruquintinib
This report displays the potential drug interactions for the following 2 drugs:
- dabrafenib
- fruquintinib
Interactions between your drugs
dabrafenib fruquintinib
Applies to: dabrafenib and fruquintinib
GENERALLY AVOID: Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of fruquintinib, which is primarily metabolized by the isoenzyme. Concomitant use with efavirenz, a moderate CYP450 3A4 inducer, decreased fruquintinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 4% and 32%, respectively. Reduced efficacy of fruquintinib may occur.
MANAGEMENT: Coadministration of fruquintinib with moderate CYP450 3A4 inducers should generally be avoided. The potential for diminished pharmacologic effects of fruquintinib should be considered during coadministration with moderate CYP450 3A4 inducers. However, if concomitant use is required, the manufacturer advises that fruquintinib may be continued at the recommended dosage.
References
- (2023) "Product Information. Fruzaqla (fruquintinib)." Takeda Pharmaceuticals America
Drug and food interactions
dabrafenib food
Applies to: dabrafenib
ADJUST DOSING INTERVAL: Food may reduce as well as delay the absorption of dabrafenib. In study subjects, administration of dabrafenib with a high-fat meal decreased peak plasma concentration (Cmax) and systemic exposure (AUC) by 51% and 31%, respectively, and delayed median Tmax by approximately 3.6 hours compared to administration in the fasted state.
MANAGEMENT: Dabrafenib should be taken at least 1 hour before or 2 hours after a meal.
References
- (2013) "Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Multikinase inhibitors
Therapeutic duplication
The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:
- dabrafenib
- fruquintinib
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.